|
|
Cambridge Healthtech Institute主办 国际会议・展示会
Drug Development China
2008年9月16~18日
美国旧金山 The Fairmont
顾问委员会
汇聚了最先进的专家。
- Li Chen, Ph.D., Chief Scientific Officer, Roche R&D Center (China) Ltd.
- Ling Chen, Ph.D., Director General, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences
- Shaoyu Chen, Senior Counsel, Development & Regulatory Law Group, Amgen Inc.
- Joong Myung Cho, Ph.D., President & CEO, CrystalGenomics, Inc. (South Korea)
- Ming Guo, Ph.D., Vice President, Pharmaceutical Sciences & Manufacturing; General Manager, Ascenta (Shanghai) R&D Center; Ascenta Therapeutics, Inc.
- Canwen Jiang, M.D., Ph.D., Head of Genzyme Science (R&D) China, Genzyme
- Xian-Ping Lu, CEO & Chief Scientific Officer, Shenzhen Chipscreen Biosciences Ltd.
- Eric Meyers, President, China Preclinical Management Services
- Purvish M. Parikh, Ph.D., Professor, Medical Oncology, Indian Co-operative Oncology Network (ICON-ARO)
- Rickey Pate, MBA, JD, Director of Global Tax, Eli Lilly and Company
- Sofie Qiao, Ph.D., President and COO, LEAD Therapeutics, Inc.
- Jun Ren, M.D., Ph.D., Executive Director, Clinical Trials Coordination, Peking University School of Oncology / Beijing Cancer Hospital
- Greg B. Scott, President and Founder, ChinaBio® Accelerator/Life Science Angels
- Michael Shi, Director and Biomarker Project Leader, Exploratory Oncology Development, Novartis Oncology
- Mansour Yaïch, Ph.D., Vaccine Development Director, PATH
- Zhengyu Yuan, Ph.D., President and CEO, MicuRx Pharmaceuticals, Inc.
- Benny Zee, Ph.D., Assistant Dean of Research for the Faculty of Medicine, Director of the Centre for Clinical Trials, School of Public Health, Chinese University of Hong Kong (CUHK)
- Ji Zhang, Ph.D., Director, DMPK, GlaxoSmithKline R&D China
- Haizhou Zhang, Ph.D., Vice President, China Operations, China Preclinical Management Services
- Guoxin Zhu, Ph.D., CSO, Head of China Chemistry, Discovery Chemistry Research Technology, Eli Lilly Asia, Inc., Shanghai Rep. Office
|
语言选择
|